Aurobindo Pharma shares dropped more than 3% after the United States Food and Drug Administration (US FDA) completed its inspection at Unit II of Apitoria Pharma Private Limited, a wholly-owned subsidiary of Aurobindo, located in Telangana. The inspection, which happened from September 23 to 27, 2024, resulted in 10 observations from the US FDA.
The 10 observations made by the US FDA are procedural in nature. Aurobindo Pharma claimed that these will be addressed within the regulatory response time. The firm stated that the inspection was finished on September 27, 2024, at 8:00 PM.
As of 3:06 pm, Aurobindo Pharma shares were trading 3.21% down at Rs 1,462.85 on the NSE.
Disclaimer: Stock market investments are subject to market risks. The information provided in this article is for informational purposes only and should not be construed as financial or investment advice. Readers are advised to seek independent financial advice before making any investment decisions. The author and the publication are not responsible for any losses incurred based on the information provided in this article.
